Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2015

View Archived Issues

BMS initiates phase I trial of BMS-986171

Blood level of UCH-L1 is a biomarker of traumatic brain injury

Researchers at CSIC present alpha-synuclein overexpressing mouse model

miRagen Therapeutics begins first clinical trial for antifibrosis candidate MRG-201

Protein Sciences receives U.S. Department of Defense grant to develop adenovirus vaccine

Enterome Bioscience and Gustave Roussy establish microbiome collaboration in immune-oncology

Daratumumab granted U.S. orphan status for diffuse large B-cell lymphoma

The FDA grants orphan drug designation to Bone Therapeutics' bone marrow derived cells

Early clinical data for Macrogenics' MGA-271

Daiichi Sankyo presents preclinical and phase I results for DS-3032b

Amplyx Pharmaceuticals secures funding to advance APX-001

FDA approves Tagrisso to treat certain patients with NSCLC

SOM Biotech and Vall d'Hebron complete trial in patients with TTR amyloidosis

Genfit reveals design of phase III trial of elafibranor for NASH

Finnish clearance for first-in-human study of Lymfactin for breast cancer-associated lymphedema

Auven releases promising findings from pivotal study of Seciera for dry eye disease

Two Baxalta hemophilia A products approved in Europe, U.S.

Preclinical data on TBI-302 that led to advancement into phase I for HCC

Abeta42-targeting MAb MEDI-1814 well tolerated in patients with Alzheimer's disease

Piramal Enterprises reports cannabinoid CB1 receptor antagonists

Isis Pharmaceuticals describes gapped oligonucleotides

Mitsubishi Tanabe Pharma presents ENPP2 inhibitors

Merck & Co. and Mochida Pharmaceutical divulge FIXa inhibitors

NIP-565: a JAK-1 inhibitor for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.